First COVID-19 Booster Dose in the General Population: A Systematic Review and Meta-Analysis of Willingness and Its Predictors

Galanis, Petros; Vraka, Irène; Katsiroumpa, Aglaia; Σίσκου, Όλγα; Konstantakopoulou, Olympia; Κατσούλας, Θεόδωρος; Mariolis‐Sapsakos, Theodoros; Kaitelidou, Daphne

doi:10.3390/vaccines10071097

Cited by 43 publications

(69 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings were higher than the results of previously published meta-analysis by Norhayati et al, which reported a pooled proportion of COVID-19 vaccine acceptance from 170 studies in 50 countries of 61% (95% CI: 59–64%) [ 93 ]. A recently published systematic review and meta-analysis by Galanis et al estimated the acceptance of a COVID-19 vaccine booster dose at a level of 79%—similar to our estimate—among the general public based on the inclusion of 14 studies [ 107 ].…”

Section: Discussionsupporting

confidence: 69%

COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

The World Health Organization (WHO) recommended coronavirus disease 2019 (COVID-19) booster dose vaccination after completing the primary vaccination series for individuals ≥18 years and most-at-risk populations. This study aimed to estimate the pooled proportion of COVID-19 vaccine booster dose uptake and intention to get the booster dose among general populations and healthcare workers (HCWs). We searched PsycINFO, Scopus, EBSCO, MEDLINE Central/PubMed, ProQuest, SciELO, SAGE, Web of Science, Google Scholar, and ScienceDirect according to PRISMA guidelines. From a total of 1079 screened records, 50 studies were extracted. Meta-analysis was conducted using 48 high-quality studies according to the Newcastle-Ottawa Scale quality assessment tool. Using the 48 included studies, the pooled proportion of COVID-19 vaccine booster dose acceptance among 198,831 subjects was 81% (95% confidence interval (CI): 75–85%, I2 = 100%). The actual uptake of the booster dose in eight studies involving 12,995 subjects was 31% (95% CI: 19–46%, I2 = 100%), while the intention to have the booster dose of the vaccine was 79% (95% CI: 72–85%, I2 = 100%). The acceptance of the booster dose of COVID-19 vaccines among HCWs was 66% (95% CI: 58–74%), I2 = 99%). Meta-regression revealed that previous COVID-19 infection was associated with a lower intention to have the booster dose. Conversely, previous COVID-19 infection was associated with a significantly higher level of booster dose actual uptake. Subgroup analyses revealed that the pooled booster dose acceptance in the WHO region of the Americas, which did not include any actual vaccination, was 77% (95% CI: 66–85%, I2 = 100%). The pooled acceptance of the booster dose in the Western Pacific was 89% (95% CI: 84–92%, I2 = 100), followed by the European region: 86% (95% CI: 81–90%, I2 = 99%), the Eastern Mediterranean region: 59% (95% CI: 46–71%, I2 = 99%), and the Southeast Asian region: 52% (95% CI: 43–61%, I2 = 95). Having chronic disease and trust in the vaccine effectiveness were the significant predictors of booster dose COVID-19 vaccine acceptance. The global acceptance rate of COVID-19 booster vaccine is high, but the rates vary by region. To achieve herd immunity for the disease, a high level of vaccination acceptance is required. Intensive vaccination campaigns and programs are still needed around the world to raise public awareness regarding the importance of accepting COVID-19 vaccines needed for proper control of the pandemic.

show abstract

Section: Discussionsupporting

confidence: 69%

COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The prevalence of individuals who ‘definitely intended’ to receive a booster vaccine was high in both samples (73% and 67%, respectively). Similar high rates of acceptance have been reported regarding the primary vaccine course, estimated at 84% (UK) and 82% (Australia) in one recent meta-analysis [ 13 ] and 67% (Europe) and 76% (Oceana) in another [ 32 ], and are comparable to a recent global estimate (79%) for booster intent [ 17 ]. However, to the best of our knowledge, the present study is the first to measure booster intentions in Australia specifically [ 17 ].…”

Section: Discussionsupporting

confidence: 77%

“…At present, however, very few studies have investigated the intention to receive a booster vaccine. A recent meta-analysis reported on just twelve studies that have investigated the predictors of booster intent, with the majority focusing on sociodemographic factors and limited to Asian samples [ 17 ]. Additionally, despite concern regarding the COVID-19 virus and positive perceptions of the COVID-19 vaccine (i.e., psychological perceptions) being some of the strongest predictors of the intention to receive a first COVID-19 vaccine, only five studies included predictors investigating the former, and four the latter.…”

Section: Introductionmentioning

confidence: 99%

Drivers of the Intention to Receive a COVID-19 Booster Vaccine: Insights from the UK and Australia

Barnes

Colagiuri

2022

Vaccines

View full text Add to dashboard Cite

As the global pandemic perpetuates, keeping the population vaccinated will be imperative to maintain societal protection from the SARS-CoV-2 (COVID-19) virus. However, while empirical evidence regarding predictors of the intention to receive a first COVID-19 vaccine has amassed, our understanding regarding the psychological and behavioral drivers of continued COVID-19 vaccination remains limited. In this pre-registered study (UK: AsPredicted#78370|Australia: AsPredicted#81667), factors predicting the intention to receive a COVID-19 booster vaccine were investigated in two adult samples from the UK (N = 1222) and Australia (N = 1197) that were nationally representative on factors of age, gender, and geographic location. High levels of booster intent were found (73% and 67%, respectively). Exploratory Structural Equation Modelling (ESEM) revealed three key predictors of the intention to receive a booster vaccine that emerged across both UK and Australian samples: concern regarding the COVID-19 virus, positive perceptions of the COVID-19 vaccines, and the perceived severity of side effects experienced to the last COVID-19 vaccine dose. Several additional factors (age, months since the last COVID-19 vaccine, familiarity with side effects, and regularly receiving the influenza vaccine) were present in the Australian dataset. These findings provide important evidence that targeting psychological perceptions of the COVID-19 vaccine and virus may serve to maintain participation in the COVID-19 vaccination programme, paving the way for future behavioural research in this area.

show abstract

“…No matter the type of COVID-19 vaccine administered, the waning of humoral responses is observed, especially in older adults, immunosuppressed individuals, and males [ 22 , 23 ]. Meanwhile, the willingness to receive a booster dose has decreased in communities, and “doubt on the necessity of further vaccination” is mentioned as the main reason [ 24 , 25 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity

et al. 2022

View full text Add to dashboard Cite

Background: There is debate on the necessity of booster doses of COVID-19 vaccination, especially in countries with limited resources. Methods: This cross-sectional study was conducted in a referral laboratory in Tehran, Iran. The level of COVID-19 antibodies was measured and compared between individuals regarding the number of COVID-19 vaccine shots. Results: In this study, 176 individuals with a mean age of 36.3 (±11.7) years participated. A total of 112 individuals received two doses of the COVID-19 vaccine, and 64 individuals received three doses. Level of all antibodies was higher in those who received three doses than in those who received two doses of the COVID-19 vaccine. Considering the SARS-CoV-2 Spike IgG, the difference was not statistically significant but for the SARS-CoV-2 RBD IgG and SARS-CoV-2 NAB the difference was statistically significant. Regarding to the background variables, receiving influenza vaccine in the past year, history of autoimmune diseases and past medical history of chicken pox showed a significant association with the number of vaccine doses received. Their effects on the outcome variables assessed with multivariate logistic regression analysis. Conclusion: The results of our study show that a booster dose of the COVID-19 vaccine enhances the antibody response.

show abstract

First COVID-19 Booster Dose in the General Population: A Systematic Review and Meta-Analysis of Willingness and Its Predictors

Cited by 43 publications

References 85 publications

COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis

COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis

Drivers of the Intention to Receive a COVID-19 Booster Vaccine: Insights from the UK and Australia

Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity

Contact Info

Product

Resources

About